Traders should monitor mid-2026 for initial STRO-004 clinical data, which could serve as a major value catalyst. The improved financial efficiency and extended cash runway reduce near-term dilution risk and support continued development of Sutro’s high-potential dual-payload ADC platform.
STRO drugs
STRO drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 24 $23.57entry
- T+1 · 8mo ago −0.30%α −0.86% · $23.50
- T+5 · 8mo ago +5.69%α +6.11% · $24.91
- T+20 · 7mo ago +50.74%α +41.84% · $35.53
- T+60 · 5mo ago +25.71%α +11.39% · $29.63
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Sutro Biopharma reported its 2025 financial results, highlighted by a 65% year-over-year increase in revenue to $102.5 million, primarily from its Astellas and Ipsen collaborations, while significantly reducing R&D and G&A expenses. The company also announced clinical progress across its ADC pipeline, including dosing in a Phase 1 trial for STRO-004 and advancement of its dual-payload programs, supported by a $110 million capital raise extending its cash runway into Q2 2028.
Key Financial Metrics
Key Facts
- Revenue increased 65% YoY to $102.5 million in 2025, up from $62.0 million in 2024, driven by collaboration income from Astellas and Ipsen.
- Total operating expenses dropped from $300.5 million in 2024 to $260.9 million in 2025, with R&D spending down 34% despite ongoing clinical development.
- Cash, cash equivalents, and marketable securities totaled $141.4 million as of December 31, 2025, and a $110 million equity raise extended the cash runway into at least Q2 2028.
- STRO-004 Phase 1 trial completed dosing in three cohorts, with initial clinical data expected mid-2026.
- STRO-227, a dual-payload ADC targeting PTK7, remains on track for IND submission in 2026.
- Astellas began patient dosing in a dual-payload iADC trial, triggering a $10 million milestone expected in Q2 2026, and a second program triggered a $7.5 million payment in late 2025.
Financial Impact
Revenue increased by $40.5 million YoY while reducing operating expenses by $39.6 million, improving financial efficiency. The $110 million capital raise significantly extends operational runway.
Risk Factors
- As a clinical-stage company, Sutro remains dependent on clinical trial outcomes, which are inherently uncertain.
- Future revenue is heavily tied to collaboration milestones, which may be delayed or not achieved.
- The company has a stockholders' equity deficit of $132.5 million, indicating ongoing reliance on external financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260829 |
Track record
8 reports on STRO
2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +5.09% at T+1 after the Nov 12, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $9.82 to $9.32 Now $9.32 +5.09% ▲ +5.09% +3.18% vs SPY
- Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $10.61 to $10.17 Now $9.32 −12.16% ▼ −4.15% −3.78% vs SPY
- Aug 12, 202613w ago 8-K Bullish 7/10 No price data
- Aug 12, 202613w ago Press Release Mixed 6/10 Entry $21.30 to $21.31 Now $9.32 −56.24% ▲ +0.05% −0.65% vs SPY
- Apr 22, 202629w ago DEFA14A Neutral 3/10 Entry $34.83 to $33.33 Now $9.32 −73.24% ▼ −4.31% −5.09% vs SPY
- Apr 19, 202630w ago Press Release Bullish 7/10 Entry $34.58 to $34.35 Now $9.32 −73.05% ▼ −0.67% −0.01% vs SPY
- Mar 23, 202634w ago S-3 Bearish 6/10 Entry $23.57 to $23.50 Now $9.32 +60.46% ▲ +0.30% +0.86% vs SPY
- Mar 23, 202634w ago Press Release Bullish 7/10 Viewing Entry $23.57 to $23.50 Now $9.32 −60.46% ▼ −0.30% −0.86% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers